Literature DB >> 18544953

A new prognostic staging system for hepatocellular carcinoma: value of the biomarker combined Japan integrated staging score.

Satoshi Kitai1, Masatoshi Kudo, Yasunori Minami, Kazuomi Ueshima, Hobyung Chung, Satoru Hagiwara, Tatsuo Inoue, Emi Ishikawa, Shunsuke Takahashi, Yutaka Asakuma, Seiji Haji, Yukio Osaki, Hiroko Oka, Toshihito Seki, Hiroshi Kasugai, Yo Sasaki, Takashi Matsunaga.   

Abstract

OBJECTIVES: The Japan Integrated Staging (JIS) score has been reported to have good stratification ability in patients with hepatocellular carcinoma (HCC). However, the JIS score could not estimate malignant grade of HCC. The aim of this study was to evaluate the performance of a new staging system: the biomarker combined JIS (bm-JIS) which includes three tumor markers: alpha-fetoprotein (AFP), Lens culinaris agglutinin-reactive AFP and des-gamma-carboxy prothrombin with the conventional JIS score.
METHODS: A total of 1,924 HCC patients were included in this study. We compared their overall survival, the stratification ability and suitability as a prognostic model according to the bm-JIS score and the conventional JIS score.
RESULTS: There were significant differences between the survival curves for all bm-JIS scores. For the conventional JIS scores of 0, 1, 2 and 3, the survival curves differed greatly according to the bm-JIS score (p < 0.0001). The independent homogenizing ability and the stratification value of the JIS score and the bm-JIS score determined by the likelihood ratio test using the Cox proportional hazard regression model showed the bm-JIS score to have a higher value(chi2 = 717.348) than the JIS score (chi2 = 668.91).
CONCLUSIONS: The bm-JIS score showed superior stratification ability and thus was found to be a better predictor of the prognosis than the conventional JIS score, especially for the patients with good prognosis. Copyright 2008 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18544953     DOI: 10.1159/000122599

Source DB:  PubMed          Journal:  Intervirology        ISSN: 0300-5526            Impact factor:   1.763


  12 in total

Review 1.  Staging systems for hepatocellular carcinoma: Current status and future perspectives.

Authors:  Akiyoshi Kinoshita; Hiroshi Onoda; Nao Fushiya; Kazuhiko Koike; Hirokazu Nishino; Hisao Tajiri
Journal:  World J Hepatol       Date:  2015-03-27

Review 2.  A discussion of serum albumin level in advanced-stage hepatocellular carcinoma: a medical oncologist's perspective.

Authors:  Ozgur Tanriverdi
Journal:  Med Oncol       Date:  2014-10-15       Impact factor: 3.064

3.  High expression of HEF1 predicts a poorer prognosis of hepatocellular carcinoma: A retrospective study.

Authors:  Mei Li; Shumei Yan; Muyan Cai; Jiabin Lu; Meifang Zhang; Ping Yang; Rongzhen Luo
Journal:  Mol Clin Oncol       Date:  2015-12-11

4.  Des-gamma-carboxy prothrombin stimulates human vascular endothelial cell growth and migration.

Authors:  Su-Bo Wang; Yan-Na Cheng; Shu-Xiang Cui; Julia Li Zhong; S G Ward; Li-Rui Sun; Ming-Hui Chen; Norihiro Kokudo; Wei Tang; Xian-Jun Qu
Journal:  Clin Exp Metastasis       Date:  2009-03-05       Impact factor: 5.150

Review 5.  Usefulness of staging systems and prognostic scores for hepatocellular carcinoma treatments.

Authors:  Xavier Adhoute; Guillaume Penaranda; Jean Luc Raoul; Patrice Le Treut; Emilie Bollon; Jean Hardwigsen; Paul Castellani; Hervé Perrier; Marc Bourlière
Journal:  World J Hepatol       Date:  2016-06-18

6.  A new staging system is more discriminant than conventional staging systems for unresectable hepatocellular carcinoma.

Authors:  Bai-Hong Zhang; Xiang-Hui Wang; Hong-Yun Yue; Chang-Quan Ling
Journal:  J Cancer Res Clin Oncol       Date:  2009-11-15       Impact factor: 4.553

7.  Prognostic value of preoperative alpha-fetoprotein (AFP) level in patients receiving curative hepatectomy- an analysis of 1,182 patients in Hong Kong.

Authors:  Miu Yee Chan; Wong Hoi She; Wing Chiu Dai; Simon Hing Yin Tsang; Kenneth Siu Ho Chok; Albert Chi Yan Chan; Jame Fung; Chung Mau Lo; Tan To Cheung
Journal:  Transl Gastroenterol Hepatol       Date:  2019-07-11

8.  Clinical features and prognostic factors in patients with bone metastases from hepatocellular carcinoma after liver transplantation.

Authors:  Jian He; Zhao-Chong Zeng; Jia Fan; Jian Zhou; Jing Sun; Bing Chen; Ping Yang; Bin-Liang Wang; Bo-Heng Zhang; Jian-Ying Zhang
Journal:  BMC Cancer       Date:  2011-11-22       Impact factor: 4.430

9.  The Degree of Lipiodol Accumulation Can Be an Indicator of Successful Treatment for Unresectable Hepatocellular Carcinoma (HCC) Patients - in the Case of Transcatheter Arterial Chemoembolization (TACE) and External Beam Radiotherapy (EBRT).

Authors:  Ping Yang; Zhao-Chong Zeng; Bin-Liang Wang; Jian-Ying Zhang; Jia Fan; Jian Zhou; Yong Hu
Journal:  J Cancer       Date:  2016-07-04       Impact factor: 4.207

10.  Alpha-fetoprotein and novel tumor biomarkers as predictors of hepatocellular carcinoma recurrence after surgery: a brilliant star raises again.

Authors:  Quirino Lai; Fabio Melandro; Rafael S Pinheiro; Andrea Donfrancesco; Bashir A Fadel; Giovanni B Levi Sandri; Massimo Rossi; Pasquale B Berloco; Fabrizio M Frattaroli
Journal:  Int J Hepatol       Date:  2012-06-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.